Palisade Bio, Inc. PALI 深 沪
已收盘 01-30 16:00:00 美东时间
1.49
-0.120
-7.45%
华盛通- 最 高1.63
- 今 开1.60
- 成交量 654.81万股
- 最 低 1.45
- 昨 收 1.61
- 总市值 1358.76万
- 52周最高 2.64
- 市盈率 静 --
- 换手率 71.81%
- 52周最低 0.53
- 委 比 -3.23%
- 总股本 911.92万
- 历史最高 18405.00
- 量 比 1.77
- 振 幅 11.18%
- 历史最低 0.53
- 每 手 1
- 风险率 0.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board
Palisade Bio announced the appointment of IBD experts Laurent Peyrin-Biroulet, MD, PhD, and David T. Rubin, MD, to its Clinical Advisory Board. Their expertise includes ulcerative colitis, Crohn’s disease, and clinical trial design. Palisade Bio is advancing PALI-2108 toward Phase 2 development for ulcerative colitis and fibrostenotic Crohn’s disease. The drug is a once-daily oral PDE4 inhibitor prodrug targeting the terminal ileum and colon, aim...
01-29 13:45
Palisade Bio Two Abstracts Selected For Poster Presentation At Two Premier International Inflammatory Bowel Diseases Meetings
Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the
01-16 21:33
Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences
Palisade Bio, Inc. announced that two abstracts on its lead program, PALI-2108, were selected for poster presentations at two major IBD meetings in early 2026. PALI-2108 is a gut-targeted PDE4B inhibitor designed for localized delivery to the terminal ileum and colon, aiming to minimize systemic exposure and side effects. The first presentation, at the Crohn’s & Colitis Congress 2026 in Las Vegas, will discuss how PALI-2108 rapidly restores immun...
01-16 13:30
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
Palisade Bio Secures Up To $500K Strategic Investment From The Crohn's & Colitis Foundation, To Advance PALI-2108 For Ulcerative Colitis And Fibrostenotic Crohn's Disease
PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and fibrostenotic Crohn's
01-07 21:18
Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108
Palisade Bio, Inc. has received a strategic equity investment of up to $500,000 from the Crohn’s & Colitis Foundation, supporting the development of PALI-2108, a targeted PDE4 inhibitor for ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD). PALI-2108, designed for local delivery to the terminal ileum and colon, aims to address significant unmet needs by targeting inflammation and fibrosis with minimal systemic effects. The investme...
01-07 13:15
美股大行评级 | 潜在涨幅1391.05%！Maison Solutions获Ascendiant Capital升目标价至4.5美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Maison Solutions"买入"评级，目标价从4.25美元升至4.5美元；HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从39美元升至50美元
2025-12-31 10:25
美股机会日报 | 凌晨3点美联储公布12月会议纪要；百度无人车布局英国，盘前大涨5%
凌晨3点美联储公布12月会议纪要；金价大幅反弹！有分析指黄金多头可能正在回归；百度盘前大涨5%，公司无人车布局英国，已成全球第一自动驾驶出行服务商>>
2025-12-30 23:57
美股牛股 | Sidus Space涨超33%，完成发行1620万美元股份；DigitalBridge涨近10%
Sidus Space涨超33%，完成发行1620万美元股份，此前获国防部合同；SLS涨超16%，关键实验取得积极进展；DigitalBridge涨近10%，获软银40亿美元收购>>
2025-12-30 14:43
美股大行评级 | 潜在涨幅908.06%！Piper Sandler首予Palisade Bio(PALI)"超配"评级，目标价25美元
今日重点评级关注：Needham：维持Autolus Therapeutics"买入"评级，目标价从10美元升至11美元；BTIG：维持Praxis Precision Medicine"买入"评级，目标价从507美元升至843美元
2025-12-30 10:04
